HeartBeat.bio AG logo

HeartBeat.bio AG

REINVENTING CARDIAC DRUG DISCOVERY

22 employees · est. 2021 · Vienna, Austria

VS
Solid IO logo

Solid IO

ENDING THE GUESSWORK IN CANCER CARE | Patient-specific organ-on-chip technology for precision oncology & immunotherapy

8 employees · est. 2025 · Helsinki, Finland

HeartBeat.bio AG is the older company (2021 vs 2025); HeartBeat.bio AG is the larger of the two.

Side-by-Side Comparison

HeartBeat.bio AG Solid IO
Founded
2021 older 2025
Headquarters
Vienna, Austria Helsinki, Finland
Employees
22 larger 8
Industry
Biotechnology Not tracked yet
Funding Stage
Seed Seed
Total Funding
$6.00M $800.00K
Funding Rounds
2 1
Services
Not tracked yet Tumor-on-chip platform, Patient-specific treatment insights, Immunotherapy research support, Early-stage clinical trial facilitation
Target Customers
Not tracked yet Pharmaceutical Companies, Biotech Firms, Cancer Clinics, Oncologists, Researchers
Taxonomy
Cardiac Organoids, Drug Discovery, Heart Failure, Cardiomyopathy, Myocardial Infarction, 3D Disease Modelling, High-Throughput Screening, Cardiovascular Regeneration, Cardiotoxicity, Cardio-Oncology, IPS Cells, AI-supported Analysis, Genetic Cardiomyopathies, Vienna BioCenter Organ-on-chip Technology, Precision Oncology, Immunotherapy, Tumor Microenvironment, Clinical Trials Optimization, Drug Development Acceleration, Biomarker Validation, Personalized Immunotherapies, Cancer Research, Patient-specific Treatment, Oncology Data Insights, Pharmaceutical Innovation, Biotech Collaboration, Precision Medicine
Website
heartbeat.bio solid-io.com
HeartBeat.bio AG logo

About HeartBeat.bio AG

HeartBeat.bio AG is a biotechnology startup that aims to reinvent cardiac drug discovery through its innovative approach. The company, founded in 2021 and headquartered in Austria, is focusing on the development of a high-throughput human organoid cultivation, screening, and AI-supported data analys...

Solid IO logo

About Solid IO

Solid IO, founded in 2025 and headquartered in Finland, is pioneering advancements in precision oncology and immunotherapy through its unique organ-on-chip technology. The company's slogan, "ENDING THE GUESSWORK IN CANCER CARE," underscores its commitment to providing patient-specific data that empo...

We will tell you when either one moves

BounceWatch watches HeartBeat.bio AG and Solid IO for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at HeartBeat.bio AG and Solid IO — by email.

Frequently Asked Questions

HeartBeat.bio AG — REINVENTING CARDIAC DRUG DISCOVERY. Solid IO — ENDING THE GUESSWORK IN CANCER CARE | Patient-specific organ-on-chip technology for precision oncology & immunotherapy. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
HeartBeat.bio AG has raised $6.00M while Solid IO has raised $800.00K.
HeartBeat.bio AG and Solid IO operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare HeartBeat.bio AG with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at HeartBeat.bio AG on 11 Sep 2024, and Solid IO on 13 Nov 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy